Elucid — Valuation, Funding & Investors

Recent changes

Sep 4, 2026Sep 4, 2026Raised $55M Series D BioSpace
Sep 4, 2026Sep 4, 2026Elucid Raises $55M for AI Heart-Disease Imaging Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Sep 4, 2026	Series D	$55M	—	IAG Capital PartnersElevage Medical Technologies	Pulse story

Latest Pulse

Sep 4, 2026Elucid Raises $55M for AI Heart-Disease ImagingBoston-based Elucid raised $55 million in an oversubscribed Series D to expand its FDA-cleared Plaque-IQ software, which uses AI to read plaque risk from routine CT scans.→

Coverage Timeline

newest first

Sep 4, 2026FUNDINGElucid Raises $55M for AI Heart-Disease Imaging$55M Series D→

All Coverage

FUNDING· Sep 3, 2026

Elucid Raises $55M for AI Heart-Disease Imaging

FUNDING$55M Series D

Elucid Raises $55M for AI Heart-Disease Imaging

Boston-based Elucid raised $55 million in an oversubscribed Series D to expand its FDA-cleared Plaque-IQ software, which uses AI to read plaque risk from routine CT scans.

Sep 3, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

BioSpaceValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction